Roth Capital Predicts Weaker Earnings for Aurora Cannabis

Aurora Cannabis Inc. (TSE:ACB) – Research analysts at Roth Capital cut their Q2 2026 earnings per share (EPS) estimates for shares of Aurora Cannabis in a research report issued to clients and investors on Wednesday, August 6th. Roth Capital analyst W. Kirk now anticipates that the company will post earnings per share of $0.16 for the quarter, down from their prior estimate of $0.32. The consensus estimate for Aurora Cannabis’ current full-year earnings is ($0.22) per share. Roth Capital also issued estimates for Aurora Cannabis’ Q3 2026 earnings at $0.81 EPS and Q4 2026 earnings at ($0.13) EPS.

Aurora Cannabis Trading Up 16.4%

TSE:ACB opened at C$7.18 on Monday. The stock has a market cap of C$392.80 million, a PE ratio of -8.87 and a beta of 2.71. The stock’s 50-day moving average is C$6.54 and its two-hundred day moving average is C$6.72. Aurora Cannabis has a fifty-two week low of C$4.95 and a fifty-two week high of C$9.90. The company has a debt-to-equity ratio of 18.72, a current ratio of 3.42 and a quick ratio of 2.48.

Insiders Place Their Bets

In related news, Senior Officer Andre Jerome bought 8,000 shares of Aurora Cannabis stock in a transaction that occurred on Friday, June 20th. The stock was purchased at an average cost of C$5.83 per share, for a total transaction of C$46,640.00.

Aurora Cannabis Company Profile

Aurora Cannabis, headquartered in Edmonton, Canada, cultivates and sells medicinal and recreational cannabis through a portfolio of brands that includes Aurora, CanniMed, Daily Special, MedReleaf, and San Rafael ’71. Although the company primarily operates in Canada, it has expanded internationally through medical cannabis exporting agreements or cultivation facilities in more than 20 countries.